Is Starlink Set For The Largest IPO In History?

He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000!

Kerri-Ann Millar net worth and biography

Kerri-Ann Millar Biography and Net Worth

CFO of Cue Biopharma

Kerri-Ann Millar serves as the Chief Financial Officer. Before joining Cue Biopharma, Ms. Millar served as Corporate Controller for Flexion Therapeutics, Inc., a biopharmaceutical company focused on the development of local therapies for the treatment of patients with osteoarthritis, where she developed the finance function for the newly public company to support the commercialization of its first approved drug. Prior to Flexion Therapeutics, she served as a Finance Specialist for Curis, Inc., a biotechnology company focused on the development of oncology treatments. Prior to Curis, Ms. Millar spent over 10 years in audit and finance functions at several investment banks in the Boston area and four years at PricewaterhouseCoopers. She earned a B.S. in Accounting and Finance from Boston University and is a Certified Public Accountant.

How old is Kerri-Ann Millar?: Ms. Millar is currently 54 years old. There are 5 older executives and no younger executives at Cue Biopharma. The oldest executive at Cue Biopharma is Mr. Colin G. Sandercock J.D., MSE, Senior VP, General Counsel & Secretary, who is 67 years old. Learn More on Kerri-Ann Millar's age.
How do I contact Kerri-Ann Millar?: The corporate mailing address for Ms. Millar and other Cue Biopharma executives is 21 ERIE STREET, CAMBRIDGE MA, 02139. Cue Biopharma can also be reached via phone at (617) 949-2680 and via email at [email protected]. Learn More on Kerri-Ann Millar's contact information.
Has Kerri-Ann Millar been buying or selling shares of Cue Biopharma?: Kerri-Ann Millar has not been actively trading shares of Cue Biopharma during the last quarter. Most recently, Kerri-Ann Millar sold 1,251 shares of the business's stock in a transaction on Friday, October 1st. The shares were sold at an average price of $14.21, for a transaction totalling $17,776.71. Learn More on Kerri-Ann Millar's trading history.
Who are Cue Biopharma's active insiders?: Cue Biopharma's insider roster includes Kerri-Ann Millar (CFO), Daniel Passeri (CEO), Kenneth Pienta (Insider), and Anish Suri (Insider). Learn More on Cue Biopharma's active insiders.
Are insiders buying or selling shares of Cue Biopharma?: In the last year, Cue Biopharma insiders bought shares 1 times. They purchased a total of 30,000 shares worth more than $30,900.00. The most recent insider tranaction occured on December, 16th when CEO Daniel R Passeri bought 30,000 shares worth more than $30,900.00. Insiders at Cue Biopharma own 12.3% of the company. Learn More about insider trades at Cue Biopharma.
Information on this page was last updated on 12/16/2024.

Kerri-Ann Millar Insider Trading History at Cue Biopharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
10/1/2021	Sell	1,251	$14.21	$17,776.71
8/29/2018	Buy	1,000	$8.48	$8,480.00

Kerri-Ann Millar Buying and Selling Activity at Cue Biopharma

Cue Biopharma Company Overview

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $1.07

$1.01

$1.22

50 Day Range

MA: $1.32

$0.94

$1.87

2 Week Range

Now: $1.07

$0.45

$3.20

Volume

451,012 shs

Average Volume

453,450 shs

Market Capitalization

$67.78 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.66

Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong

From Brownstone Research | Ad

Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.

Click here to watch this demo and decide for yourself.